%0 Journal Article %A Juan Carlos Kaski %A Steffen Gloekler %A Roberto Ferrari %A Kim Fox %A Bernard I Lévy %A Michel Komajda %A Panos Vardas %A Paolo G Camici %T Role of ivabradine in management of stable angina in patients with different clinical profiles %D 2018 %R 10.1136/openhrt-2017-000725 %J Open Heart %P e000725 %V 5 %N 1 %X In chronic stable angina, elevated heart rate contributes to the development of symptoms and signs of myocardial ischaemia by increasing myocardial oxygen demand and reducing diastolic perfusion time. Accordingly, heart rate reduction is a well-known strategy for improving both symptoms of myocardial ischaemia and quality of life (QOL). The heart rate-reducing agent ivabradine, a direct and selective inhibitor of the I f current, decreases myocardial oxygen consumption while increasing diastolic time, without affecting myocardial contractility or coronary vasomotor tone. Ivabradine is indicated for treatment of stable angina and chronic heart failure (HF). This review examines available evidence regarding the efficacy and safety of ivabradine in stable angina, when used as monotherapy or in combination with beta-blockers, in particular angina subgroups and in patients with stable angina with left ventricular systolic dysfunction (LVSD) or HF. Trials involving more than 45 000 patients receiving treatment with ivabradine have shown that this agent has antianginal and anti-ischaemic effects, regardless of age, sex, severity of angina, revascularisation status or comorbidities. This heart rate-lowering agent might also improve prognosis, reduce hospitalisation rates and improve QOL in angina patients with chronic HF and LVSD. %U https://openheart.bmj.com/content/openhrt/5/1/e000725.full.pdf